A detailed history of Alp Invest Partners B.V. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Alp Invest Partners B.V. holds 42,297 shares of MDGL stock, worth $13 Million. This represents 6.43% of its overall portfolio holdings.

Number of Shares
42,297
Previous 84,595 50.0%
Holding current value
$13 Million
Previous $23.7 Million 62.13%
% of portfolio
6.43%
Previous 8.5%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$212.22 - $292.96 $8.98 Million - $12.4 Million
-42,298 Reduced 50.0%
42,297 $8.98 Million
Q2 2024

Aug 09, 2024

SELL
$193.33 - $291.99 $4.09 Million - $6.18 Million
-21,149 Reduced 20.0%
84,595 $23.7 Million
Q1 2024

May 03, 2024

SELL
$171.37 - $283.23 $18.1 Million - $29.9 Million
-105,744 Reduced 50.0%
105,744 $28.2 Million
Q4 2023

Feb 02, 2024

BUY
$120.4 - $237.13 $25.5 Million - $50.2 Million
211,488 New
211,488 $48.9 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.28B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Alp Invest Partners B.V. Portfolio

Follow Alp Invest Partners B.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alp Invest Partners B.V., based on Form 13F filings with the SEC.

News

Stay updated on Alp Invest Partners B.V. with notifications on news.